Cornell Pochily Investment Advisors Inc. Sells 670 Shares of Thermo Fisher Scientific Inc. $TMO

Cornell Pochily Investment Advisors Inc. decreased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 10.5% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 5,715 shares of the medical research company’s stock after selling 670 shares during the period. Cornell Pochily Investment Advisors Inc.’s holdings in Thermo Fisher Scientific were worth $2,317,000 as of its most recent filing with the SEC.

Several other hedge funds have also added to or reduced their stakes in the stock. CBIZ Investment Advisory Services LLC increased its stake in shares of Thermo Fisher Scientific by 137.5% in the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock worth $28,000 after purchasing an additional 33 shares in the last quarter. Anderson Financial Strategies LLC purchased a new position in shares of Thermo Fisher Scientific in the first quarter worth about $30,000. Keystone Global Partners LLC purchased a new position in shares of Thermo Fisher Scientific in the first quarter worth about $31,000. DiNuzzo Private Wealth Inc. increased its stake in shares of Thermo Fisher Scientific by 406.7% in the second quarter. DiNuzzo Private Wealth Inc. now owns 76 shares of the medical research company’s stock worth $31,000 after purchasing an additional 61 shares in the last quarter. Finally, IMA Advisory Services Inc. purchased a new position in shares of Thermo Fisher Scientific in the first quarter worth about $35,000. Institutional investors own 89.23% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on TMO shares. Wall Street Zen downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Sunday, September 7th. Evercore ISI reduced their price objective on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an “outperform” rating for the company in a research note on Tuesday, July 8th. William Blair initiated coverage on shares of Thermo Fisher Scientific in a research note on Monday, August 18th. They set an “outperform” rating for the company. Robert W. Baird boosted their price objective on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an “outperform” rating in a research note on Thursday, July 24th. Finally, Wells Fargo & Company reduced their price objective on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an “overweight” rating for the company in a research note on Thursday, July 24th. Fifteen investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and an average target price of $585.37.

Thermo Fisher Scientific Price Performance

TMO stock opened at $525.07 on Friday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $611.49. The stock has a market cap of $198.27 billion, a PE ratio of 30.37, a P/E/G ratio of 2.88 and a beta of 0.77. The firm has a 50 day simple moving average of $481.27 and a two-hundred day simple moving average of $447.60.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping analysts’ consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business had revenue of $10.86 billion during the quarter, compared to analysts’ expectations of $10.68 billion. During the same quarter in the previous year, the company earned $5.37 EPS. The business’s quarterly revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific’s payout ratio is currently 9.95%.

Insider Transactions at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 400 shares of the business’s stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $500.50, for a total value of $200,200.00. Following the completion of the sale, the chief executive officer directly owned 113,762 shares in the company, valued at approximately $56,937,881. The trade was a 0.35% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CAO Joseph R. Holmes sold 385 shares of the business’s stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the completion of the sale, the chief accounting officer owned 2,319 shares of the company’s stock, valued at approximately $1,142,408.97. The trade was a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 30,066 shares of company stock worth $14,182,963. 0.33% of the stock is currently owned by insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.